Astrocyte in Neurological Disease: Pathogenesis and Therapy

Meihui Huang, Aoyang Long, Lingjia Hao, Ziyun Shi, Mengqi ZhangMedComm 2025 · DOI

TL;DR

This review highlights the critical, often dual, role of astrocytes in neurological diseases, detailing how their dysfunction contributes to pathogenesis through neuroinflammation, synaptic disruption, and blood-brain barrier breakdown. It then explores promising therapeutic strategies targeting astrocytes, from modulating their activation states to advanced gene and exosome therapies, paving the way for future precision medicine approaches.

What Problem Does This Paper Address?

The central nervous system (CNS) is a complex ecosystem where astrocytes, once thought of as mere support cells, are now recognized as active players in both maintaining brain health and driving disease. Neurological disorders like Alzheimer's, Parkinson's, multiple sclerosis, and stroke are characterized by astrocyte dysfunction. This paper addresses the critical need to understand the multifaceted roles of astrocytes in these diseases – how they can be both protective and detrimental – and to consolidate the rapidly evolving landscape of therapeutic strategies that target these cells. The challenge lies in harnessing their beneficial functions while mitigating their harmful contributions, a complex task given their diverse roles and the intricate nature of neurological disease.

Methods

This paper is a comprehensive review, not an experimental study. Therefore, it doesn't employ novel experimental methods or algorithms. Instead, it synthesizes existing research by:

  • Systematic Literature Review: Analyzing a vast body of published studies, preclinical data, and emerging clinical trials related to astrocyte function in neurological diseases.
  • Bibliometric Analysis: Utilizing network visualization techniques to identify key research clusters and temporal trends in astrocyte research over the past five years, highlighting areas of intense focus and evolving interests.
  • Conceptual Framework Development: Organizing complex information into clear categories, such as the dual roles of astrocytes (neurotoxic vs. neuroprotective), their metabolic functions, and various therapeutic approaches.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Astrocytes are not passive bystanders: They are dynamic cells with a profound impact on neuronal health, synaptic function, and the integrity of the blood-brain barrier (BBB). Their dysfunction is a central theme in many neurological diseases.
  • The "dual-use" nature of astrocytes: Astrocytes can switch between beneficial (neuroprotective, anti-inflammatory) and detrimental (neurotoxic, pro-inflammatory) states (A1 vs. A2 phenotypes). Understanding this switch is key to therapeutic intervention.
  • Metabolic dysregulation is a major driver: Aberrant glucose, lipid, and amino acid metabolism in astrocytes, particularly linked to APOE4 genotypes in Alzheimer's, directly contributes to neurodegeneration and inflammation.
  • The BBB is a critical astrocyte interface: Astrocytes play a pivotal role in maintaining BBB integrity, and their dysfunction can lead to its breakdown, exacerbating disease progression.
  • Therapeutic potential is vast and diverse: Targeting astrocytes offers a promising avenue for treating neurological disorders. This includes modulating their activation, correcting metabolic imbalances, and employing cutting-edge gene and exosome-based therapies.

Key Results

The paper doesn't present quantitative results from new experiments. Instead, it synthesizes findings from numerous studies:

  • Pathogenesis: Astrocyte dysfunction is linked to neuroinflammation (e.g., A1 phenotype releasing inflammatory cytokines), synaptic dysfunction (e.g., altered glutamate-glutamine cycle), and BBB disruption (e.g., altered tight junction proteins, APOE4 effects).
  • Metabolic Abnormalities: Studies show reduced glucose transporters (GLUT1) in AD, altered lipid metabolism linked to APOE4, and mitochondrial dysfunction in astrocytes, all contributing to disease progression.
  • Therapeutic Promise:
    • Modulating Activation: Targeting the A1/A2 phenotype balance shows promise.
  • Metabolic Interventions: Restoring mitochondrial OXPHOS and targeting lipid metabolism pathways are being explored.
  • Gene Therapy: CRISPR-Cas9 and AAV vectors are being investigated for correcting genetic defects and delivering therapeutic genes.
  • Exosome Technology: Astrocyte-derived exosomes are being explored for their ability to deliver therapeutic molecules (miRNAs, proteins) and modulate inflammation.

Limitations and Future Work

  • Astrocyte Heterogeneity: The paper acknowledges the significant heterogeneity of astrocyte populations across different brain regions and within disease states, which complicates targeted therapies.
  • Specificity and Side Effects: Developing therapies with sufficient cell-type specificity to avoid unintended effects on non-astrocytic cells remains a challenge.
  • Biomarker Development: The need for robust in vivo biomarkers to monitor astrocyte reactivity states is highlighted.
  • Optimal Therapeutic Windows: Determining the precise timing for intervention is crucial, as astrocyte modulation effects can vary dramatically with disease stage.

Future Directions:

  • Multi-omics Integration: Combining transcriptomics, proteomics, and metabolomics to gain a deeper understanding of astrocyte networks.
  • Clinical Translation: Accelerating the translation of preclinical findings into clinical trials.
  • Personalized Medicine: Developing patient-specific approaches based on individual astrocyte phenotypes and disease contexts.
  • Advanced Delivery Systems: Further refining nanotechnology and exosome-based delivery for precise targeting and reduced immunogenicity.
  • AI-driven Drug Design: Leveraging artificial intelligence to discover and optimize astrocyte-targeted therapeutics.

Summary updated

Abstract

Astrocytes, as key support cells in the central nervous system, maintain homeostasis in the brain through mechanisms such as ionic homeostasis regulation, metabolic support, synaptic modulation, and neuroinflammatory regulation. Recent studies have shown that astrocyte dysfunction is closely related to the pathologic processes of various neurological diseases, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke. In this review, we comprehensively summarize the dual roles of astrocytes in neurological diseases: on one hand, their aberrant activation can exacerbate disease progression by mediating neuroinflammation, synaptic dysfunction, and blood-brain barrier disruption; on the other hand, their metabolic disorders, such as lipid droplet accumulation, mitochondrial dysfunction, and oxidative stress imbalance, further drive neurodegeneration. In terms of therapeutic strategies, interventions targeting astrocytes, such as modulation of activation phenotype, metabolic reprogramming, gene therapy, and innovative therapies based on exosomes and nanotechnology, show great promise. In the future, we may integrate multi-omics technologies and deepen clinical translational research to systematically analyze the spatial heterogeneity of astrocytes and their dynamic regulatory networks at different stages of the disease, in order to elucidate the precise mechanisms of their roles in the pathological process, and thus provide multidimensional theoretical support for the design of targeted therapeutic strategies.
BibTeX
@inproceedings{huang2025astrocyte,
  author = {Meihui Huang and Aoyang Long and Lingjia Hao and Ziyun Shi and Mengqi Zhang},
  title = {{Astrocyte in Neurological Disease: Pathogenesis and Therapy}},
  booktitle = {MedComm},
  year = {2025},
  doi = {10.1002/mco2.70299},
}
Figure